Research Article

Myocardial Infarction and AGT p.Thr174Met Polymorphism: A Meta-Analysis of 7657 Subjects

Yan-yan Li, Hui Wang, Hao Wang, and Yang-yang Zhang

1Clinical Research Center, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
2Department of Geriatrics, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
3Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
4Department of General Practice, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Correspondence should be addressed to Yan-yan Li; lyynjmu123@126.com

Received 7 December 2020; Revised 25 March 2021; Accepted 23 April 2021; Published 4 May 2021

Academic Editor: Rosario D. C. Hirata

Copyright © 2021 Yan-yan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. It has been suggested that the angiotensinogen (AGT) gene rs4762 (p.Thr174Met) polymorphism might be associated with myocardial infarction (MI) risk, but the study results are still debatable. Objective and Methods. In order to explore the relationship between AGT p.Thr174Met polymorphism and MI risk, the current meta-analysis involving 7657 subjects from 11 individual studies was conducted. Results. A significant association between AGT p.Thr174Met polymorphism and MI was found under recessive (OR: 2.26, 95% CI: 1.35-3.77, \( P = 0.002 \)), dominant (OR: 1.131, 95% CI: 1.016-1.260, \( P = 0.024 \)), codominant (OR: 2.198, 95% CI: 1.334-3.621, \( P = 0.002 \)), and additive (OR: 1.363, 95% CI: 1.132-1.641, \( P = 0.001 \)) genetic models. In the Asian subgroup, significantly increased MI risk was found under all genetic models (\( P < 0.05 \)). No significant association between AGT p.Thr174Met polymorphism and MI was found under all genetic models in the Caucasian subgroup (\( P > 0.05 \)). Conclusions. AGT p.Thr174Met variant might increase MI risk, especially within the Asian population. The Met174 allele of AGT p.Thr174Met might confer the risk for MI.

1. Introduction

Myocardial infarction (MI) is a serious type of coronary artery disease (CAD) that has high morbidity and mortality rates [1, 2]. MI may be caused by coronary artery critical stenosis or occlusion and myocardial ischemic necrosis based on coronary artery atherosclerosis; however, the pathogenesis has not yet been completely clarified [3, 4]. Risk factors, such as smoking, diabetes mellitus, hypercholesterolemia, gender, and age, are confirmed to increase MI susceptibility. Basic research has shown that individual gene heterogeneity is another risk factor for MI [5]. Hence, MI is a multifactorial disease resulting from heredity and environment factors [6, 7]. In the past few years, many studies that investigated the relationship between gene polymorphisms and MI focused primarily on enzymes and key proteins related to the regulation and metabolism of the cardiovascular system. For example, renin-angiotensin system (RAS), lipid metabolism, coagulation, fibrinolysis, and inflammation system have become hot research spots [8–10]. RAS plays an important role in cardiomyocyte growth regulation, water and electrolyte balance, and blood pressure regulation.

Angiotensinogen (AGT) is the main member of the RAS system. Human AGT is produced in the liver, digested by renin enzyme to produce angiotensin I (Ang I), and then converted to angiotensin II (Ang II) by angiotensin-converting enzyme (ACE). Ang II induces the proliferation and hypertrophy of human vascular smooth muscle cells (VSMCs), increases the expression of platelet-derived growth factor, inhibits fibrinolytic activity, and promotes blood thrombogenesis, low-density lipoprotein (LDL) deposition, oxidation, and endocytosis in the vascular wall [11]. As a salt-sensitive gene, the human AGT, located at 1q42-43, is 13 kb in length and contains five exons and four introns. In 1992, Corvol et al. [12] discovered a point mutation substituting thymine (T) for cytosine (C) at position 521 of the exon 2 (3389C>T, rs4762), resulting in methionine (Met) in place of threonine (Thr) at amino acid 174 (p.Thr174Met). The
Met174 allele of AGT p.Thr174Met might increase the plasma levels of AGT and Ang II, thereby increasing vasoconstriction, VSMC proliferation, and lipid deposition; this allele participates in the pathogenesis of atherosclerosis, hypertension, and MI and increases the MI risk [11, 13–15].

Although studies on the relationship between AGT p.Thr174Met polymorphism and MI were widely performed, their results varied widely. In 2006, Ning et al. [16] found that AGT Met174 allele increased MI risk in the Chinese population. In 2008, Xie et al. [17] also found that the MM genotype and M allele of AGT p.Thr174Met might be a risk factor for MI in an Uighur ethnic population in Xinjiang of China. By contrast, in 1995, Tietet et al. [18] reported that the AGT locus had no significant impact on the risk of nonfatal MI in the French population.

This meta-analysis including 3944 patients with MI and 3713 controls was conducted to confirm the relationship between AGT p.Thr174Met polymorphism and MI.

2. Publication Search and Inclusion Criteria

The terms “myocardial infarction”, “angiotensinogen”, and “polymorphism” were used to search the China Biological Medicine Database China National Knowledge Infrastructure, Embase, PubMed, and Web of Science. Studies were retrieved within the publication year ranging from 1995 to 2018 (the last research updated on April 20, 2021).

The inclusion criteria for the studies were as follows: (a) evaluation of the AGT p.Thr174Met polymorphism and MI and (b) diagnosis of MI in accordance with the diagnosis criteria promulgated by the World Health Organization in 1979 or the global universal definition of MI by the European Society of Cardiology, American College of Cardiology Foundation, American Heart Association, and World Heart Federation in 2012. MI was diagnosed if the patient had a conclusive positive history of MI or presented with ST elevation or non-ST elevation.

2.1. Data Extraction. Data were obtained according to a standard protocol. Repeated literature, studies that did not meet the inclusion criteria, and studies with limited data were removed. Overlapping portions of data were used only once. The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of all eligible studies. The abstracted data were composed of the following items: the first author’s name, publication year, region, number of genotypes, genotyping, study design, matching criteria, total number of cases and controls, P value for Hardy-Weinberg equilibrium (HWE), and NOS score.

2.2. Statistical Analysis. All of the statistical analysis would be performed by using the STATA 12.0 software (StataCorp, College Station, TX) and review manager 5.0, and P value was set at <0.05 for most of the statistical tests.

In order to assess the association between AGT p.Thr174Met polymorphism and MI, the pooled odds ratio (OR) corresponding to 95% confidence interval (CI) was used. In the present meta-analysis, four genetic models as the recessive (MetMet vs. ThrMet+ThrThr, MM vs. TT+TM), dominant (MetMet+ThrMet vs. ThrThr, MM+TM vs. TT), codominant (MetMet vs. ThrThr, MM vs. TT), and additive genetic models (Met vs. Thr, M vs. T) were used. The chi-square test was used to evaluate the HWE of the genotype distribution.

In order to calculate the heterogeneity between studies, the chi-square-based Q-test was used with significance set at \( P < 0.10 \) [19]. The inconsistency index \( I^2 \) was calculated to assess the heterogeneity variation. The pooled OR was determined using Z test, and the random-effects model was applied when there was heterogeneity among the studies (DerSimonian and Laird method) [20]. Otherwise, the fixed-effects model was used (Mantel-Haenszel method) [21].

The potential publication bias would be estimated by using a funnel plot. The funnel plot asymmetry would be assessed by using Egger’s linear regression test on the natural logarithm scale of the OR [22].

3. Results

3.1. Studies and Populations. Of the 20 papers produced by our initial search of literature, 11 studies met the inclusion criteria. Of the 9 dropped studies, four papers were double publications, two papers were reviews, and three papers were not associated with the AGT p.Thr174Met polymorphism. No study was excluded for the reason of deviating from HWE.

Total data were extracted from 3944 patients with MI and 3713 controls (Table 1) [16–18, 23–30]. Patients were from China, Russia, Germany, Austria, United Kingdom, Poland, Mexico, United Arab Emirates, and France. Two ethnicities present were Asian and Caucasian.

The NOS scores in all of the included studies were no less than 6 stars, which implied that all of the eligible studies were of high quality.

3.2. Pooled Analyses. Significant associations between AGT p.Thr174Met polymorphism and MI were found for recessive (OR: 2.26, 95% CI: 1.35–3.77, \( P = 0.002 \)), dominant (OR: 1.131, 95% CI: 1.016–1.260, \( P = 0.024 \)), codominant (OR: 2.198, 95% CI: 1.334-3.621, \( P = 0.002 \)), and additive (OR: 1.363, 95% CI: 1.132-1.641, \( P = 0.001 \)) genetic models (Table 2, Figures 1–4).

Further association analyses in Asian and Caucasian subgroups were performed. Significant heterogeneity was found in the overall population for all genetic models (\( P_{\text{heterogeneity}} < 0.10 \)), but no heterogeneity existed in the Asian subgroup for all genetic models (\( P_{\text{heterogeneity}} > 0.10 \)) (Table 2, Figures 1–4). In the Caucasian subgroup, significant heterogeneity was also found for dominant and additive genetic models (\( P_{\text{heterogeneity}} < 0.10 \)) (Table 2, Figures 2 and 4), and no significant heterogeneity existed for recessive or codominant genetic models (\( P_{\text{heterogeneity}} > 0.10 \)) (Table 2, Figures 1 and 3). Hence, ethnicity was the main heterogeneity source in the current meta-analysis.

In the Asian subgroup analysis, AGT p.Thr174Met polymorphism significantly increased MI risk for recessive (OR: 4.08, 95% CI: 2.35–7.09, \( P = 5.73 \times 10^{-7} \), \( P_{\text{heterogeneity}} = 0.58 \)), dominant (OR: 1.444, 95% CI: 1.092–1.910, \( P = 0.01 \),
Table 1: Characteristics of the selected studies of the association between \( AGT \) p.Thr174Met polymorphism and myocardial infarction.

| Author                  | Year | Region     | Ethnicity | MI Minor allele frequency | Control Minor allele frequency | Genotyping     | Matching criteria       | Sample size (MI/control) | \( P \) value for HWE | NOS score (stars) |
|-------------------------|------|------------|-----------|---------------------------|-------------------------------|----------------|-------------------------|--------------------------|------------------------|---------------------|
| Tiret et al. [18]       | 1995 | UK, France | Caucasian | 118                       | 116                           | AS-PCR         | BMI, ethnicity           | 630/741                  | 0.73                   | 6                   |
| Frossard et al. [28]    | 1998 | UAE        | Asian     | 0.1                       | 0.1                           | PCR-RFLP       | Age, sex, BMI, ethnicity | 40/61                    | 0.26                   | 6                   |
| Chistiakov et al. [23]  | 1999 | Russia     | Caucasian | 0.322                     | 0.108                         | PCR-RFLP       | Ethnicity               | 45/60                    | 0.69                   | 6                   |
| Gardemann et al. [24]   | 1999 | Germany    | Caucasian | 0.120                     | 0.120                         | PCR            | Age, ethnicity           | 1058/1192                | 0.79                   | 6                   |
| Liu et al. [25]         | 2002 | China      | Asian     | 0.095                     | 0.094                         | PCR            | Sex, ethnicity           | 58/90                    | 0.32                   | 6                   |
| Renner et al. [26]      | 2005 | Austria    | Caucasian | 0.139                     | 0.138                         | PCR            | BMI, ethnicity           | 1370/733                 | 0.98                   | 6                   |
| Ning et al. [16]        | 2006 | China      | Asian     | 0.175                     | 0.096                         | PCR-RFLP       | Ethnicity               | 114/204                  | 0.36                   | 6                   |
| Sun et al. [27]         | 2006 | China      | Asian     | 0.170                     | 0.098                         | PCR            | Age, sex, BMI, ethnicity | 112/128                  | 0.43                   | 6                   |
| Xie et al. [17]         | 2008 | China      | Asian     | 0.217                     | 0.153                         | PCR-RFLP       | Age, sex, ethnicity      | 175/167                  | 0.06                   | 6                   |
| Konopka et al. [29]     | 2011 | Poland     | Caucasians| 0.255                     | 0.153                         | PCR-RFLP       | Sex, ethnicity           | 100/95                   | 0.34                   | 6                   |
| Isordia-Salas et al. [30]| 2018| Mexico     | Caucasians| 0.118                     | 0.085                         | PCR-RFLP       | Age, sex, BMI, ethnicity | 242/242                  | 0.54                   | 6                   |

Case-control study design was used in all studies. AS-PCR: allele-specific PCR; BMI: body mass index; MI: myocardial infarction; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism; TT: ThrThr; TM: ThrMet; MM: MetMet; UAE: United Arab Emirates; UK: United Kingdom.
Table 2: Summary results of meta-analysis on association between AGT p.Thr174Met polymorphism and myocardial infarction.

| Genetic model | Pooled OR (95% CI) | Z value | P value | Studies | Sample size | $P_{\text{heterogeneity}}$ ($I^2\%$) |
|---------------|--------------------|---------|---------|---------|-------------|-----------------------------------|
| **Recessive** |                    |         |         |         |             |                                   |
| Overall group | 2.26 (1.35-3.77)   | 3.11    | 0.002*  | 11      | 3944/3713   | 0.03** (49%)                     |
| Asian subgroup| 4.08 (2.35-7.09)   | 5.00    | 0.001** | 5       | 499/650     | 0.58 (0%)                        |
| Caucasian subgroup | 1.18 (0.79-1.76) | 0.80    | 0.24    | 6       | 3445/3063   | 0.54 (0%)                        |
| **Dominant**  |                    |         |         |         |             |                                   |
| Overall group | 1.131 (1.016-1.260)| 2.25    | 0.024*  | 11      | 3944/3713   | 0.058* (44.0%)                   |
| Asian subgroup| 1.444 (1.092-1.910)| 2.58    | 0.010*  | 5       | 499/650     | 0.786 (0%)                       |
| Caucasian subgroup | 1.085 (0.966-1.219) | 0.96 | 0.338 | 6 | 3445/3063 | 0.027** (60.5%) |
| **Codominant**|                    |         |         |         |             |                                   |
| Overall group | 2.198 (1.334-3.621)| 3.09    | 0.002*  | 11      | 3944/3713   | 0.051** (45.1%)                  |
| Asian subgroup| 3.928 (2.222-6.945)| 4.70    | 0.063** | 5       | 499/650     | 0.685 (0%)                       |
| Caucasian subgroup | 1.195 (0.799-1.788) | 0.87 | 0.386 | 6 | 3445/3063 | 0.442 (0%) |
| **Additive**  |                    |         |         |         |             |                                   |
| Overall group | 1.363 (1.132-1.641)| 3.26    | 0.001*  | 11      | 3944/3713   | 0.002** (63.5%)                  |
| Asian subgroup| 1.701 (1.350-2.143)| 4.51    | 0.063** | 5       | 499/650     | 0.642 (0%)                       |
| Caucasian subgroup | 1.185 (0.976-1.438) | 1.71 | 0.087 | 6 | 3445/3063 | 0.027** (60.5%) |

*P<0.05, **P<0.10; CI: confidence interval; OR: odds ratio; MI: myocardial infarction; recessive genetic model: MM vs. TM+TT; dominant genetic model: TM+MM vs. TT; codominant genetic model: MM vs. TT; additive genetic model: total M vs. total T.

Figure 1: Forest plot of AGT p.Thr174Met polymorphism associated with myocardial infarction stratified by ethnicity using a recessive genetic model (MM vs. TM+TT).
heterogeneity = 0.786), codominant (OR: 3.928, 95% CI: 2.222-6.945, \( P = 2.60 \times 10^{-6}, \) \( P_{\text{heterogeneity}} = 0.685 \)), and additive (OR: 1.701, 95% CI: 1.350-2.143, \( P = 6.48 \times 10^{-6}, \) \( P_{\text{heterogeneity}} = 0.642 \)) genetic models (Table 2, Figures 1–4).

However, no significant association was found between AGT p.Thr174Met polymorphism and MI in the Caucasian subgroup for recessive (OR: 1.18, 95% CI: 0.79-1.76, \( P = 0.42, \) \( P_{\text{heterogeneity}} = 0.54 \)), dominant (OR: 1.085, 95% CI: 0.966-1.219, \( P = 0.171, \) \( P_{\text{heterogeneity}} = 0.027 \)), codominant (OR: 1.195, 95% CI: 0.799-1.788, \( P = 0.386, \) \( P_{\text{heterogeneity}} = 0.442 \)), or additive (OR: 1.185, 95% CI: 0.976-1.438, \( P = 0.087, \) \( P_{\text{heterogeneity}} = 0.027 \)) genetic models (Table 2, Figures 1–4).

A cumulative analysis over time was performed using the recessive genetic model (Figure 5). No significant association was found between AGT p.Thr174Met polymorphism and MI before 2006 (OR: 1.47, 95% CI: 0.92-2.37, \( P = 0.071 \)).
2006, after the study by Sun et al. was added in the current meta-analysis, a significant association between them was detected (OR: 1.72, 95% CI: 1.03-2.89, \( P = 0.039 \)).

### 3.3. Bias Diagnostics

Funnel plot and Egger’s test were used to assess the publication bias of the individual studies. No visual publication bias was found according to the funnel plot of the overall studies using a recessive genetic model (Figure 6). Further, no significant difference was detected in Egger’s test, suggesting lack of publication bias in this meta-analysis by using the recessive genetic model (\( T = 2.16, P = 0.059 \); Figure 7).

### 4. Discussion

In this meta-analysis, the controls comprised hospitalized individuals who matched the case group by age, sex, BMI, or ethnicity. The controls were not diagnosed with CAD by coronary angiography and had no history of cardiovascular disease in their families. Case-control study design was used.
in all of the included studies. The abstracted data quality was high because the NOS score in all of the included studies, including manuscript selection, comparability, and exposure, was no less than 6 stars.

In the entire sample population, a significant association was found between AGT p.Thr174Met polymorphism and MI for recessive (OR: 2.26), dominant (OR: 1.131), codominant (OR: 2.198), and additive (OR: 1.363) genetic models.

The different results in the two subgroups suggested that ethnicity might influence the association between AGT p.Thr174Met polymorphism and MI. Furthermore, the allelic frequencies between these ethnic groups and the differences in the matching criteria could also influence the results. In addition, the negative results in the Caucasian population were possibly influenced by the small number of included studies. Only six studies were included in the Caucasian sub-

group, indicating that more studies should be conducted in the future to verify the result within this population.

The cumulative analysis over time also showed that the significant association between MI and AGT p.Thr174Met variant was found after 2006. It was suggested that the significant association between them was confirmed after 2006 which might be related with more individual included studies. The bias diagnostics showed that no publication bias was detected which suggested that no obvious systemic error existed in the current meta-analysis.

MI is a multifactorial disease that varies among race, ethnicity, and geographic region. Different morbidity rates were found among different races and ethnicities. Although the AGT p.Thr174Met mutation is not in the range of conserved sequences of the AGT protein core serpin domain [31, 32], this mutation involves the conversion between hydrophobic Met and hydrophilic Thr, and in the 3D structure of AGT protein, the adjacent Thr at 174 is Thr206. Therefore, it is speculated that the result of this mutation may be the interaction between amino acids with different polarities and the conformational change that increases the activity of AGT in RAS. Thus, it affects the activation or inactivation of the corresponding components in the coagulation and fibrinolysis system and promotes the formation of MI [33].

In 2012, Xu et al. [34] performed a meta-analysis on the association of AGT p.Thr174Met polymorphism and CAD risk and found no significant overall association (OR: 1.07, CI: 0.93-1.22) in the Asian and Caucasian population. Their meta-analysis included 16 individual studies. CAD includes angina pectoris, MI, silent myocardial ischemia, ischemic cardiomyopathy, and sudden death. The different results between all types of CAD, single MI risk, and CAD diseases and diabetes mellitus, were not accounted for in this study.

A further meta-analysis found association of the AGT p.Thr174Met polymorphism with MI risk [35] in both Caucasian and Asian populations, but only six individual studies were included. Compared with the previously published meta-analyses on the topic, higher number of individual studies was included in the present work. The present meta-analysis confirmed the significant association between them again by analyzing more studies.

This meta-analysis has some limitations. The sample size is relatively small, and large-scale research on the relationship between MI and AGT p.Thr174Met polymorphism remains insufficient. Other AGT genetic polymorphisms such as -217G>A (rs5049), -532C>T (rs5046), 12775G>A (rs943580), -6T>C (rs5051), 4072C>T orMet235Thr (rs699), 11535C>A (rs7079), and 6309C>T (rs2493132) might also influence the AGT activity. Additionally, environmental factors, such as race, region, smoking status, hyperlipidemia, and diabetes mellitus, were not accounted for in this study.

5. Conclusions

AGT p.Thr174Met variant increases MI risk, especially in the Asian population. This finding needs to be further confirmed by further research in the future.
Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Y.L. and H.W. conceived and designed the experiments. Y.L. and Y.Z. analyzed the data. Y.L. and H.W. contributed reagents/material/analysis tools. Y.L. wrote the manuscript. Y.L. and H.W. were responsible for reference collection and data management. Y.L. was responsible for statistical analyses and paper writing. Y.L. was responsible for the study design. Yan-yan Li and Hui Wang contributed equally to this work.

Acknowledgments

This work was funded by the National Natural Science Foundation of China (NSFC 81100073 to Dr. Yan-yan Li), Excellent Young and Middle-Aged Teachers Assistance Program of Nanjing Medical University for Dr. Yan-yan Li (2013-2015, JX2161015034), Jiangsu Overseas Research & Training Program for University Prominent Young & Middle-Aged Teachers and Presidents (2014), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). We thank all our colleagues working in the First Affiliated Hospital of Nanjing Medical University.

References

[1] S. Koudstaal, S. J. Jansen of Lorkeers, F. J. Slochteren et al., “Assessment of coronary microvascular resistance in the chronic infarcted pig heart,” Journal of Cellular and Molecular Medicine, vol. 17, no. 9, pp. 1128–1135, 2013.

[2] R. H. Chen, Y. G. Li, K. L. Jiao et al., “Overexpression of Sema3a in myocardial infarction border zone decreases vulnerability of ventricular tachycardia post-myocardial infarction in rats,” Journal of Cellular and Molecular Medicine, vol. 17, no. 5, pp. 608–616, 2013.

[3] S. Q. Liu, D. Roberts, A. Kharitonenkov et al., “Endocrine protection of ischemic myocardium by FGFr21 from the liver and adipose tissue,” Scientific Reports, vol. 3, no. 1, p. 2767, 2013.

[4] E. Duah, R. K. Adapala, N. al-Azzam et al., “Cysteiny1 leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT2 and CysLT1 receptors,” Scientific Report, vol. 3, no. 1, p. 3274, 2013.

[5] A. Porter, A. R. Assali, A. Zahalka et al., “Impaired fasting glucose and outcomes of ST-elevation acute coronary syndrome treated with primary percutaneous intervention among patients without previously known diabetes mellitus,” American Heart Journal, vol. 155, no. 2, pp. 284–289, 2008.

[6] M. A. Hlatky, T. Quertermous, D. B. Boothroyd et al., “Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease,” American Heart Journal, vol. 154, no. 6, pp. 1035–1042, 2007.

[7] M. E. Marenberg, N. Risch, L. F. Berkman, B. Floderus, and U. de Faire, “Genetic susceptibility to death from coronary heart disease in a study of twins,” The New England Journal of Medicine, vol. 330, no. 15, pp. 1041–1046, 1994.

[8] B. Bigalke, H. Langer, T. Geisler, S. Lindemann, and M. Gawaz, “Platelet glycoprotein VI: a novel marker for acute coronary syndrome,” Seminars in Thrombosis and Hemostasis, vol. 33, no. 2, pp. 179–184, 2007.

[9] Y. Y. Li, “Plasminogen activator inhibitor-1 4G/5G gene polymorphism and coronary artery disease in the Chinese Han population: a meta-analysis,” PLoS One, vol. 7, no. 4, article e33511, 2012.

[10] Y. Y. Li, “Intercellular adhesion molecule-1 E469K gene polymorphism and coronary artery disease in the Chinese population: a meta-analysis involving 3065 subjects,” Clinical Cardiology, vol. 35, no. 1, pp. 55–60, 2012.

[11] S. S. Wang, Y. Q. Wu, X. S. Cheng, and K. C. Cheng, “Relationship between angiotensin-converting enzyme and angiotensinogen gene polymorphism and coronary artery disease,” Journal of Nanchang University(Medical Science), vol. 50, no. 8, pp. 8–11, 2010.

[12] P. Corvol, X. Jeunemaitre, A. Charru, and F. Soubrier, “Can the genetic factors influence the treatment of systemic hypertension? The case of the renin-angiotensin-aldosterone system,” The American Journal of Cardiology, vol. 70, no. 12, pp. D14–D20, 1992.

[13] S. C. Ning, A. P. Zhang, H. E. Shen, Z. Q. Li, and X. Yi, “Relationship between myocardial infarction and angiotensin gene T174M polymorphism in elderly patients,” Chinese Journal of Gerontoloty, vol. 25, no. 11, pp. 1347–1349, 2005.

[14] E. Balam-Ortiz, L. Alfaro-Ruiz, K. Carrillo et al., “Variants and haplotypes in angiotensinogen gene are associated with plasminangiotensin level in Mexican population,” The American Journal of the Medical Sciences, vol. 342, no. 3, pp. 205–211, 2011.

[15] L. Procopciuc, T. Popescu, G. Jabeleanu, D. Pop, and M. Gawaz, “Essential arterial hypertension and polymorphism of angiotensinogen M235T gene,” Journal of Cellular and Molecular Medicine, vol. 6, no. 2, pp. 245–250, 2002.

[16] S. C. Ning, L. N. Zhao, and L. J. Miao, “Clinical study of polymorphism of angiotensinogen in patients with myocardial infarction,” Clinical Medicine of China, vol. 22, no. 12, pp. 1061–1064, 2006.

[17] X. Xie, Y. T. Ma, Z. Z. Fu et al., “Association of genetic polymorphism of angiotensinogen THR174MET with myocardial infarction in Uighur nationality of Xinjiang,” Molecular Cardiology of China, vol. 8, no. 3, pp. 153–156, 2008.

[18] L. Tietj, H. Blanc, J. B. Ruidavets et al., “Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study. Projet d’Etude des Gènes de l’Hypertension Artérielle Sèvère à modérée Essentielle,” Journal of Hypertension, vol. 16, no. 1, pp. 37–44, 1998.

[19] W. G. Cochran, “The effectiveness of adjustment by subclassification in removing bias in observational studies,” Biometrics, vol. 24, no. 2, pp. 295–313, 1968.

[20] R. DerSimonian and N. Laird, “Meta-analysis in clinical trials revisited,” Contemporary Clinical Trials, vol. 45, no. Part A, pp. 139–145, 2015.
[21] N. Mantel and W. Haenszel, “Statistical aspects of the analysis of data from retrospective studies of disease,” *Journal of the National Cancer Institute*, vol. 22, no. 4, pp. 719–748, 1959.

[22] M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” *British Medical Journal*, vol. 315, no. 7109, pp. 629–634, 1997.

[23] D. A. Chistiakov, R. I. Turakulov, V. S. Moiseev, and V. V. Nosikov, “Polymorphism of angiotensinogen T174M gene and cardiovascular diseases in the Moscow population,” *Genetika*, vol. 35, no. 8, pp. 1160–1164, 1999.

[24] A. Gardemann, J. Stricker, J. Humme et al., “Angiotensinogen T174M and M235T gene polymorphisms are associated with the extent of coronary atherosclerosis,” *Atherosclerosis*, vol. 145, no. 2, pp. 309–314, 1999.

[25] Y. Liu, W. Jin, and Z. W. Jiang, “Correlation between THR174MET polymorphism of angiotensinogen gene and coronary heart disease,” *Journal of Diagnostics Concepts & Practice*, vol. 1, no. 4, pp. 231–236, 2002.

[26] W. Renner, M. Nauck, B. R. Winkelmann et al., “Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study,” *Journal of Molecular Medicine*, vol. 83, no. 3, pp. 235–239, 2005.

[27] L. Sun, W. Z. Hu, J. M. Yang et al., “Association of the angiotensin converting enzyme I/D and angiotensinogen Thr174Met gene polymorphism with acute myocardial infarction,” *Chinese Journal of Arteriosclerosis*, vol. 14, no. 8, pp. 697–700, 2006.

[28] P. M. Frossard, S. H. Hill, Y. I. Elshahat et al., “Associations of angiotensinogen gene mutations with hypertension and myocardial infarction in a gulf population,” *Clinical Genetics*, vol. 54, no. 4, pp. 285–293, 1998.

[29] A. Konopka, M. Szperl, W. Piotrowski, M. Roszczynko, and J. Stepińska, “Influence of Renin-Angiotensin system gene polymorphisms on the risk of ST-Segment-Elevation Myocardial infarction and association with coronary artery disease risk factors,” *Molecular Diagnosis & Therapy*, vol. 15, no. 3, pp. 167–176, 2011.

[30] I. Isordia-Salas, J. A. Alvarado-Moreno, R. M. Jiménez-Alvarado et al., “Association of renin-angiotensin system genes polymorphisms and risk of premature ST-elevation myocardial infarction in young Mexican population,” *Blood Coagulation & Fibrinolysis*, vol. 29, no. 3, pp. 267–274, 2018.

[31] H. Lu, L. A. Cassis, C. W. Kooi, and A. Daugherty, “Structure and functions of angiotensinogen,” *Hypertension Research*, vol. 39, no. 7, pp. 492–500, 2016.

[32] C. Wu, H. Lu, L. A. Cassis, and A. Daugherty, “Molecular and pathophysiological features of angiotensinogen: a mini review,” *American Chinese Journal of Medicine and Science*, vol. 4, no. 4, pp. 183–190, 2011.

[33] X. M. Xu, B. M. Fang, and J. Guo, “A correlation research of rs1926723, rs699, rs4762 polymorphism in AGT gene and pulmonary thromboembolism disease,” *International Journal of Laboratory Medicine & Research*, vol. 34, no. 9, pp. 1057–1059, 2013.

[34] M. Q. Xu, Z. Ye, F. B. Hu, and L. He, “Quantitative assessment of the effect of angiotensinogen gene polymorphisms on the risk of coronary heart disease,” *Circulation*, vol. 116, no. 12, pp. 1356–1366, 2007.

[35] P. Y. Hu, Y. W. Wang, X. H. Pang, and H. W. Wang, “T174M polymorphism in the angiotensinogen gene and risk of myocardial infarction: a meta-analysis,” *Genetics and Molecular Research*, vol. 14, no. 2, pp. 3767–3774, 2015.